Several prospective studies reported that pemafibrate significantly reduced ALT, GGT, and TG levels and increased HDL-cholesterol levels in 20 NAFLD patients in a 12-week single-arm prospective study [21]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.